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Abstract
Introduction Estrogen is important in the development of breast
cancer, and its biological effects are mediated primarily through
the two estrogen receptors alpha and beta. A point mutation in
the estrogen receptor alpha gene, ESR1, referred to as A908G
or K303R, was originally identified in breast hyperplasias and
was reported to be hypersensitive to estrogen. We recently
detected this mutation at a low frequency of 6% in invasive
breast tumors of the Carolina Breast Cancer Study (CBCS).
Methods In this report, we evaluated risk factors for invasive
breast cancer classified according to the presence or absence
of the ESR1 A908G mutation in the CBCS, a population-based
case-control study of breast cancer among younger and older
white and African-American women in North Carolina. Of the
653 breast tumors evaluated, 37 were ESR1 A908G mutation-
positive and 616 were mutation-negative.
Results ESR1 A908G mutation-positive breast cancer was
significantly associated with a first-degree family history of
breast cancer (odds ratio [OR] = 2.69, 95% confidence interval
[CI] = 1.15 to 6.28), whereas mutation-negative breast cancer
was not. Comparison of the two case subgroups supported this
finding (OR = 2.65, 95% CI = 1.15 to 6.09). There was also the
suggestion that longer duration of oral contraceptive (OC) use
(OR = 3.73, 95% CI = 1.16 to 12.03; Ptrend = 0.02 for use of
more than 10 years) and recent use of OCs (OR = 3.63, 95%
CI = 0.80 to 16.45; Ptrend = 0.10 for use within 10 years) were
associated with ESR1 A908G mutation-positive breast cancer;
however, ORs for comparison of the two case subgroups were
not statistically significant. Hormone replacement therapy use
was inversely correlated with mutation-negative breast cancer,
but the effect on mutation-positive cancer was unclear due to
the small number of postmenopausal cases whose tumors
carried the mutation. Mutation-negative breast cancer was
associated with several reproductive factors, including younger
age at menarche (OR = 1.46, 95% CI = 1.09 to 1.94) and
greater total estimated years of ovarian function (OR = 1.82,
95% CI = 1.21 to 2.74).
Conclusion These preliminary results suggest that OCs may
interact with the ESR1 A908G mutant receptor to drive the
development of some breast tumors.
Introduction
Most major risk factors for breast cancer are hormonal or
reproductive factors that increase exposure to estrogen and/
or progesterone [1]. The importance of estrogen in breast can-
cer development is also supported by studies demonstrating
the occurrence of marked changes in estrogen signaling and
in the expression of the two estrogen receptors (ERs), ER
alpha and ER beta, during breast tumorigenesis and progres-
sion [2-8].
Although mutations in the gene encoding ER alpha, ESR1, are
uncommon in primary breast tumors [3], a specific point muta-
tion that occurs at nucleotide 908 within codon 303 and that
is referred to as A908G or K303R was described severalPage 1 of 10
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breast hyperplasias. The A908G mutation affects the border
of the hinge and the hormone-binding domains of ESR1 and
results in an amino acid change of lysine to arginine (K303R).
Compared with the wild-type receptor, the A908G mutant
exhibited hypersensitivity to estrogen and was associated with
increased cellular proliferation at sub-physiologic levels of
estrogen [9]. The A908G mutant receptor displayed similar
affinity for estradiol as wild-type receptor but showed
enhanced binding to the TIF-2 (transcription intermediary fac-
tor-2) coactivator at low hormone levels [9]. More recent stud-
ies have also shown that the ESR1 A908G mutation in codon
303 increases phosphorylation at the Ser305 residue through
the P13 kinase/Akt signaling cascade [10], protein kinase A
[11], and p21-activated kinase [10], but the downstream func-
tional effects of this phosphorylation remain unclear.
We recently detected the ESR1 A908G mutation at a low fre-
quency of 6% in the primary invasive breast tumors of the
Carolina Breast Cancer Study (CBCS), a population-based
case-control study of mostly early stage breast cancer in North
Carolina [12]. This mutation was confirmed to be somatic in
nature and not a germline variant. Mutation-positive tumors
were more likely to have mixed lobular/ductal histology and
combined grade II (versus grade I) compared with mutation-
negative tumors.
The presence of the ESR1 A908G mutation in both breast
hyperplasias and invasive carcinomas suggests that it may be
an early genetic defect present in the breast tissue of some
women and that it, alone or in conjunction with environmental
factors, may help to drive the development of some breast
tumors. The existence of distinct subtypes of breast cancer as
defined by differences in gene expression profiles and in
expression of ER and other biomarkers has now been clearly
established [13,14]. These subtypes vary in their clinical prog-
nosis and may also be characterized by differences in risk fac-
tor profiles. Given the reported hypersensitivity of the mutant
ESR1 A908G mutant receptor to estrogen, it was of interest
to determine whether hormonal risk factors in the CBCS might
be associated with breast cancer characterized by the pres-
ence or absence of the ESR1 A908G mutation. In particular,
we evaluated exposure to exogenous hormones, such as oral
contraceptives (OCs) or hormone replacement therapy (HRT),
as well as reproductive factors linked to greater endogenous
estrogen and progesterone exposure. Our findings suggest
that OC use and first-degree family history of breast cancer
may be associated with ESR1 A908G mutation-positive
breast cancer, whereas reproductive factors associated with




This study used subjects and data from phase 1 of the CBCS,
a population-based, case-control study of invasive breast can-
cer conducted among African-American and white women
(age range, 20 to 74 years) residing in a 24-county area in
central and eastern North Carolina [15]. Both cases and con-
trols were sampled using a modification of randomized recruit-
ment [15]. Sampling probabilities ensured approximately
equal samples among cases and controls in the four age-race
groups: younger (age range, 20 to 49 years) African-American
women, older (age range, 50 to 74 years) African-American
women, younger white women, and older white women.
Details of recruitment of participants and response rates have
been published previously [15]. Incident cases of breast can-
cer diagnosed between 1 May 1993 and 30 May 1996 were
eligible as cases and were identified using the North Carolina
Central Cancer Registry's Rapid Case Ascertainment System;
of these, 861 patients with breast cancer consented to partic-
ipate in the CBCS. Clinical data and information on tumor
characteristics were obtained from medical records or direct
histopathologic review of tumor tissue as described [14]. Con-
trols were drawn from North Carolina Division of Motor Vehicle
lists for women ages 20 to 64 years and US Health Care
Financing Administration lists for women ages 65 to 74 years
and were frequency matched to cases by race and age (in 5-
year age categories). A total of 790 controls were eligible for
and consented to participate in the CBCS. All aspects of this
research were approved by the Institutional Review Board of
the University of North Carolina School of Medicine.
Tumor tissues and analysis of the ESR1 A908G mutation
Formalin-fixed paraffin-embedded (FFPE) tumor blocks were
obtained from pathology departments at participating hospi-
tals for 798 of the 861 breast cancer cases. Of these, 684
were of sufficient size to allow for the sectioning of 10-μm-
thick tissue sections for molecular analyses. Tumors were sec-
tioned and underwent standardized histopathologic review as
previously described [16]. With the hematoxylin-and-eosin-
stained slide as a guide, the area of tumor was microdissected
away from other surrounding non-tumor tissue, and DNA
lysates were prepared using proteinase K extraction.
Of the 684 tumors available for molecular studies, 653 were
successfully screened for mutations in a 104-base pair region
of exon 4 surrounding codon 303 of ESR1 by using a combi-
nation of SSCP (single-strand conformational polymorphism)
and phosphorus-33-cycle DNA sequencing as described pre-
viously [14]. The tumors that were evaluated for the ESR1
A908G mutation were more likely to be later stage (P =
0.005), of larger size (P = 0.0002), and lymph node-positive
(P = 0.006) and to exhibit higher combined grade (P = 0.04)
than tumors that were not screened, consistent with the
greater availability of tumor tissue from larger breast tumors.
However, the cases screened for mutations did not differ fromPage 2 of 10
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opausal status (P = 0.90), race (P = 0.63), ER status (P =
0.68), or tumor histology (P = 0.48).
Risk factor information
Data were obtained from cases and controls during in-person
interviews conducted by female registered nurses. The nurse-
interviewer elicited information on demographics and potential
breast cancer risk factors. Interviews were completed for 77%
(n = 861) of eligible and locatable cases and for 68% (n =
790) of eligible and locatable controls. The nurses drew a
blood sample and measured weight, height, and waist and hip
circumferences at the time of interview. Age was based on age
at diagnosis in cases or on age at selection in controls. Race
was classified according to self-report. Fewer than 2% of the
participants described themselves as races other than African-
American or white; these subjects were categorized with Afri-
can-American women for statistical analysis. Women who
used OCs or HRT for 3 months or longer were considered
ever users. Use of HRT was evaluated among postmenopau-
sal women.
Menopausal status was determined by information provided
by participants in the interview. Women who were 50 years of
age or older at the time of interview were considered to be
postmenopausal if their periods had stopped naturally, due to
surgery (hysterectomy and/or bilateral oophorectomy), or due
to chemotherapy or radiation (unrelated to the present diagno-
sis of breast cancer). Women who were less than 50 years of
age were considered postmenopausal if their periods stopped
due to natural menopause, bilateral oophorectomy, radiation,
or chemotherapy. All other women were classified as
premenopausal.
Statistical methods
To quantify the associations between reproductive, hormonal,
and other risk factors and breast cancer subtype defined by
ESR1 908G mutation status, odds ratios (ORs) and 95% con-
fidence intervals (CIs) comparing each case subgroup to con-
trols were calculated. The ORs for breast cancer were
calculated using unconditional logistic regression as imple-
mented in the SAS software program (version 8.2; SAS Insti-
tute Inc., Cary, NC, USA). Offset terms were incorporated into
models using the SAS procedure, PROC GENMOD, to
account for the sampling probabilities used to define eligible
cases and controls [15]. Potential confounding was evaluated
by including covariates in multivariate models, and these were
selected based on their role in matching or their previously
demonstrated relevance to breast cancer risk. These included
age, race, menopausal status, family history of breast cancer
in a first-degree relative, age at menarche, age at first full-term
pregnancy (AFFTP) and parity incorporated into a composite
variable (nulliparous, parity ≥ 1 and AFFTP = 26 years, parity
= 1 and AFFTP < 26 years, parity ≥ 2/AFFTP ≥ 26 years, and
parity ≥ 2 and AFFTP < 26 years), lactation (ever, never), dura-
tion of ovarian function defined as the number of years
between onset of menarche and menopause (natural or other-
wise), smoking, alcohol consumption (ever, never), and body
mass index (BMI) (less than 25, 25 to less than 30, or greater
than or equal to 30 kg/m2). Ever smoking was defined as life-
time exposure to at least 100 cigarettes. Trend tests for risk
factors with ordinal levels (for example, such as duration of OC
use) were performed, and P values were calculated using
Wald χ2 statistics.
Results
Characteristics of cases and controls
The characteristics of cases and controls in the CBCS have
been described previously [17]. Slightly more than half of the
subjects were younger than 50 years of age, approximately
half were premenopausal, and approximately 40% were Afri-
can-American. Cases were significantly more likely than con-
trols to have a first-degree family history of breast cancer.
For the present study, a total of 653 FFPE invasive breast
tumors from cases in the CBCS were screened for mutations
in a 104-base pair region of exon 4 surrounding codon 303 of
ESR1. The clinical characteristics of cases evaluated for the
ESR1 mutation have been reported previously [14]. The
majority (88%) of cases had stage 1 or 2 disease, 60% were
node-negative, 59% were ER-positive, and 79% were diag-
nosed with invasive ductal carcinoma. Of the 653 breast can-
cer cases screened, 37 (5.7%) were positive for the ESR1
A908G mutation. When analyzed according to ESR1 A908G
mutation status, tumors that were mutation-positive were of
somewhat larger size (P = 0.11), were of somewhat higher
combined grade (P = 0.03 grade II versus grade I), and were
more likely to have mixed lobular/ductal histology (P = 0.10).
However, there was no difference in ER protein expression
between mutation-positive and mutation-negative breast
tumors (P = 0.57).
Risk factors for breast cancer according to ESR1 A908G 
mutation status
Table 1 presents both minimally adjusted and more fully
adjusted ORs and 95% CIs comparing ESR1 mutation-posi-
tive cases (n = 37) and mutation-negative cases (n = 616) to
controls (n = 790). Both mutation-positive and mutation-neg-
ative cases were less likely than controls to have ever breast
fed, but this inverse association was more pronounced for
mutation-positive cases (OR = 0.29, 95% CI = 0.12 to 0.71)
than for mutation-negative cases (OR = 0.69, 95% CI = 0.53
to 0.89). Mutation-negative cases were more likely than con-
trols to have younger age at menarche (OR = 1.46, 95% CI =
1.09 to 1.94) and longer duration of ovarian function if post-
menopausal (OR = 1.82, 95% CI = 1.21 to 2.74 for 36 years
or more; Ptrend = 0.004). BMI overall was not associated with
either mutation-positive or mutation-negative cancer; stratifica-
tion on menopausal status yielded numbers of mutation-posi-Page 3 of 10
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n (%) n (%) OR1a 95% CI OR2b 95%CI n (%) OR1a 95% CI OR2b 95% CI
Age (years)
50+ 383 (48.5) 19 (51.4) c c 246 (39.9) c c
<50 407 (51.5) 18 (48.6) 370 (60.1)
Race
White 458 (58.0) 25 (67.6) c c 371 (60.2) c c
African-American 332 (42.0) 12 (32.4) 245 (39.8)
Menopausal status
Postmenopausal 435 (55.1) 22 (59.5) 1.00 --- 1.00d --- 295 (47.9) 1.00 --- 1.00d ---
Premenopausal 355 (44.9) 15 (40.5) 1.27 0.40–4.05 1.63 0.47–5.64 321 (52.1) 1.08 0.78–1.50 1.12 0.80–1.58
First-degree family history 
of BC
No 671 (88.3) 26 (72.2) 1.00 --- 1.00e --- 523 (87.0) 1.00 --- 1.00e ---
Yes 89 (11.7) 10 (27.8) 2.54 1.16–5.55 2.69 1.15–6.28 78 (13.0) 1.17 0.84–1.62 1.22 0.87–1.71
First-degree family history 
of BC and/or ovarian 
cancer
No 664 (87.4) 24 (66.7) 1.00 --- 1.00e --- 514 (85.5) 1.00 --- 1.00e ---
Yes 96 (12.6) 12 (33.3) 3.13 1.49–6.58 3.48 1.56–7.76 87 (14.5) 1.21 0.88–1.66 1.27 0.92–1.76
Prior benign breast biopsy
No 649 (82.4) 28 (80.0) 1.00 --- 1.00 --- 518 (84.2) 1.00 --- 1.00 ---
Yes 139 (17.6) 7 (20.0) 1.21 0.51–2.87 1.17 0.47–2.91 97 (15.8) 1.00 0.75–1.33 0.94 0.70–1.28
BMI
<25 250 (32.2) 15 (41.7) 1.00 --- 1.00f --- 224 (37.1) 1.00 --- 1.00f ---
25 to <30 250 (32.2) 10 (27.8) 0.73 0.32–1.69 0.78 0.32–1.90 180 (29.8) 0.87 0.66–1.14 0.83 0.63–1.10
30+ 277 (35.6) 11 (30.5) 0.80 0.34–1.89 0.76 0.29–1.98 200 (33.1) 0.85 0.64–1.12 0.80 0.60–1.08
Smoking
Never 423 (53.5) 18 (48.7) 1.00 --- 1.00g --- 322 (52.3) 1.00 --- 1.00g ---
Ever 367 (46.5) 19 (51.3) 1.16 0.59–2.27 1.04 0.49–2.19 294 (47.7) 1.08 0.87–1.34 1.11 0.88–1.41
Alcohol consumption
Never 231 (29.3) 14 (37.8) 1.00 --- 1.00h --- 178 (28.9) 1.00 --- 1.00h ---
Ever 558 (70.7) 23 (62.2) 0.79 0.39–1.63 0.74 0.32–1.71 438 (71.1) 0.95 0.75–1.22 0.88 0.67–1.16
Age at menarche (years)
14+ 203 (25.8) 10 (27.0) 1.00 --- 1.00i --- 130 (21.1) 1.00 --- 1.00i ---
13 206 (26.2) 9 (24.3) 0.96 0.38–2.44 1.22 0.43–3.41 165 (26.8) 1.28 0.95–1.75 1.38 1.01–1.91
≤12 378 (48.0) 18 (48.6) 1.12 0.50–2.50 1.42 0.57–3.53 321 (52.1) 1.36 1.04–1.79 1.46 1.09–1.94
Parity
Nulliparous 89 (11.3) 5 (13.5) 1.00 --- 1.00j --- 100 (16.2) 1.00 --- 1.00j ---
Parous 701 (88.7) 32 (86.5) 0.93 0.34–2.54 1.30 0.44–3.85 516 (83.8) 0.76 0.55–1.04 0.92 0.65–1.29
Age at first full-term 
pregnancy (years)
Nulliparous 89 (11.3) 5 (13.9) 1.00 --- 1.00j --- 100 (16.3) 1.00 --- 1.00j ---
10–19 236 (29.9) 8 (22.2) 0.74 0.23–2.39 1.03 0.28–3.79 181 (29.5) 0.82 0.57–1.16 0.99 0.67–1.46
20–24 265 (33.6) 11 (30.5) 0.82 0.27–2.52 1.14 0.35–3.74 181 (29.5) 0.73 0.51–1.03 0.88 0.60–1.27Page 4 of 10
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additional covariates did not appreciably alter the ORs.
Compared with controls, ESR1 A908G mutation-positive
cases were significantly more likely to have a first-degree fam-
ily history of breast cancer (OR = 2.69, 95% CI = 1.15 to
6.28) or a first-degree family history of breast and/or ovarian
cancer (OR = 3.48, 95% CI = 1.56 to 7.76), whereas muta-
tion-negative cases did not (OR = 1.22, 95% CI = 0.87 to
1.71 for first-degree family history of breast cancer). Mutation-
positive cases were also directly compared to the mutation-
negative cases to determine the degree of risk heterogeneity
between these two disease subtypes. First-degree family his-
tories of breast cancer (OR = 2.65, 95% CI = 1.15 to 6.09)
or of breast and/or ovarian cancer (OR = 3.15, 95% CI = 1.44
to 6.91) were both significantly associated with ESR1 A908G
mutation positivity (not shown).
As shown in Table 2, multivariate logistic regression analyses
indicated that ESR1 mutation-positive breast cancer cases
were more likely to have ever used OCs (OR = 1.72, 95% CI
= 0.66 to 4.44), but this result was not statistically significant.
An association with OC use was strongest among long-term
users (OR = 3.73, 95% CI = 1.16 to 12.03 for duration more
than 10 years) and recent users (OR = 3.63, 95% CI = 0.80
to 16.45 for use within 10 years). Women who had used OCs
for more than 10 years and within the past 10 years showed
the greatest risk of ESR1 mutation-positive breast cancer (OR
= 6.49, 95% CI = 1.32 to 31.89).
Several ORs for OC use were elevated but were not statisti-
cally significant, probably due to the small number of mutation-
positive tumors. The P values for trend among ESR1 A908G
mutation-positive cases were 0.02 for duration of OC use
(less than 5, 5 to 10, or more than 10 years) and 0.10 for
recency of OC use (10 or more years or less than 10 years).
In contrast to our findings in ESR1 mutation-positive cases,
OC use, even long-term or recent use, was not associated
with mutation-negative breast cancer. Among mutation-nega-
tive cases, the Ptrend values were 0.84 for duration of OC use
(less than 5, 5 to 10, or more than 10 years) and 0.56 for years
since stopping (10 or more years or less than 10 years). Other
measures of OC use similarly showed no associations with
ESR1 mutation-negative breast cancer.
Comparing mutation-positive to mutation-negative cases, OC
use for more than 10 years and OC use within the past 10
years were both associated with ESR1 A908G mutation
positivity, but these ORs were not statistically significant (OR
= 2.66, 95% CI = 0.81 to 8.67 for use for more than 10 years;
OR = 3.65, 95% CI = 0.86 to 15.47 for use within the past 10
25+ 198 (25.2) 12 (33.3) 1.20 0.40–3.63 1.71 0.51–5.78 152 (24.8) 0.73 0.51–1.05 0.90 0.60–1.34
Number full-term births
Nulliparous 89 (11.3) 5 (13.5) 1.00 --- 1.00j --- 100 (16.2) 1.00 --- 1.00j ---
1 141 (17.8) 5 (13.5) 0.74 0.20–2.69 0.99 0.26–3.78 117 (19.0) 0.79 0.54–1.17 0.89 0.59–1.34
2 or more 560 (70.9) 27 (73.0) 0.98 0.36–2.72 1.43 0.47–4.35 399 (64.8) 0.75 0.54–1.03 0.92 0.65–1.31
Breastfeeding
Never 476 (60.3) 26 (70.3) 1.00 --- 1.00k --- 413 (67.0) 1.00 --- 1.00k ---
Ever 314 (39.7) 11 (29.7) 0.52 0.25–1.09 0.29 0.12–0.71 203 (33.0) 0.70 0.56–0.87 0.69 0.53–0.89
Age at menopause (years) 
(postmenopausal)
<45 192 (45.6) 10 (45.5) 1.00 - 1.00d --- 117 (39.9) 1.00 --- 1.00d ---
45–49 119 (28.3) 7 (31.8) 1.13 0.42–3.08 1.47 0.45–4.79 93 (31.7) 1.38 0.96–1.97 1.39 0.95–2.03
50+ 110 (26.1) 5 (22.7) 0.82 0.27–2.53 1.32 0.36–4.77 83 (28.3) 1.39 0.95–2.03 1.50 1.00–2.24
Duration of ovarian 
function (years) 
(postmenopausal)
≤29 139 (33.2) 6 (27.2) 1.00 --- 1.00d --- 79 (27.0) 1.00 --- 1.00d ---
30–35 141 (33.6) 10 (45.4) 1.66 0.58–4.74 1.78 0.49–6.46 98 (33.4) 1.33 0.90–1.95 1.32 0.88–1.99
36+ 139 (33.2) 6 (27.2) 0.98 0.30–3.18 1.38 0.35–5.45 116 (39.6) 1.69 1.15–2.48 1.82 1.21–2.74
Ptrend 0.97 0.70 0.007 0.004
aOR1 minimally adjusted for age, race, and offsets.
bOR2 adjusted for age, race, offsets, menopausal status (except d), family history of breast cancer (except e), BMI (<25, 25 to <30, 30+) (except 
f), smoking status (never, former, current) (except g), alcohol intake (ever, never) (except h), age at menarche (<11, 11–12, 13, 14+) (except i), 
parity/age first full-term pregnancy (except j), and breast feeding (never, ever) (except k).
cORs were not calculated for age or race as these factors were part of the sampling scheme. BC, breast cancer; BMI, body mass index; CI, 
confidence interval; ESR1, estrogen receptor alpha; OR, odds ratio.
Table 1 (Continued)
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n (%) n (%) ORa 95% CI n (%) ORa 95% CI ORa 95% CI
OC use
Never 319 (40.4) 14 (37.8) 1.00 --- 224 (36.5) 1.00 --- 1.00 ---
Ever 470 (59.6) 23 (62.2) 1.72 0.66–4.44 390 (63.5) 1.15 0.87–1.52 1.53 0.61–3.84
OC duration
Never 319 (40.4) 14 (37.8) 1.00 --- 224 (36.5) 1.00 --- 1.00 ---
<5 years 232 (29.4) 8 (21.6) 1.08 0.35–3.38 194 (31.6) 1.27 0.94–1.73 1.01 0.33–3.06
5–10 years 162 (20.5) 8 (21.6) 1.75 0.53–5.77 123 (20.0) 0.95 0.67–1.35 1.79 0.59–5.43
>10 years 76 (9.6) 7 (8.9) 3.73 1.16–12.03 73 (11.9) 1.18 0.77–1.81 2.66 0.81–8.67
Ptrend 0.02 0.84 0.07
Age at first use of OCs
Never 319 (40.4) 14 (37.8) 1.00 --- 224 (36.6) 1.00 --- 1.00 ---
≤20 years 215 (27.2) 8 (21.6) 1.18 0.32–4.42 192 (31.4) 0.99 0.69–1.41 1.44 0.41–5.09
>20 years 255 (32.3) 15 (40.5) 1.81 0.71–4.63 196 (32.0) 1.20 0.89–1.60 1.56 0.61–3.96
Age at last use of OCs
Never 319 (40.4) 14 (37.8) 1.00 --- 224 (36.6) 1.00 --- 1.00 ---
≤30 years 273 (34.6) 10 (27.0) 1.18 0.36–3.90 226 (36.9) 1.10 0.80–1.52 1.39 0.45–4.25
>30 years 197 (25.0) 13 (35.1) 1.97 0.75–5.15 162 (26.5) 1.16 0.85–1.58 1.63 0.62–4.29
Year of first OC use
Never 319 (40.4) 14 (37.8) 1.00 --- 224 (36.6) 1.00 --- 1.00 ---
≤1975 389 (49.3) 19 (51.4) 1.72 0.67–4.43 292 (47.7) 1.15 0.87–1.52 1.54 0.61–3.89
>1975 81 (10.3) 4 (10.8) 1.51 0.28–8.12 96 (15.7) 0.98 0.62–1.55 1.58 0.35–7.13
First use before first full-term pregnancy
No 233 (54.8) 11 (57.9) 1.00 --- 169 (51.1) 1.00 --- 1.00 ---
Yes 192 (45.2) 8 (42.1) 0.66 0.15–2.93 162 (48.9) 1.12 0.76–1.66 0.78 0.18–3.31
Recency of OC use (years since stopping)
Never 319 (42.3) 14 (37.8) 1.00 --- 224 (39.4) 1.00 --- 1.00 ---
10+ 374 (49.5) 17 (45.9) 1.70 0.65–4.43 278 (48.8) 1.15 0.86–1.52 1.52 0.59–3.92
<10 62 (8.2) 6 (16.2) 3.63 0.80–16.45 67 (11.8) 1.06 0.65–1.72 3.65 0.86–15.47
Ptrend 0.10 0.56 0.10
OC duration and recency of use (years since stopping)
Never 319 (42.3) 14 (37.8) 1.00 --- 224 (39.4) 1.00 --- 1.00 ---
<10, <10 31 (4.1) 2 (5.4) 1.43 0.19–10.77 32 (5.6) 0.84 0.44–1.58 3.04 0.46–20.06
<10, 10+ 315 (41.7) 13 (35.1) 1.53 0.55–4.26 245 (43.1) 1.21 0.90–1.62 1.25 0.46–3.41
10+, <10 31 (4.1 4 (10.8) 6.49 1.32–31.89 35 (6.2) 1.32 0.73–2.38 3.53 0.73–17.09
10+, 10+ 59 (7.8) 4 (10.8) 1.93 0.52–7.11 33 (5.8) 0.81 0.49–1.35 3.01 0.78–11.59
Postmenopausal HRT use
Never 219 (50.3) 13 (59.1) 1.00 --- 180 (61.0) 1.00 --- 1.00 ---
Ever 216 (49.7) 9 (40.9) 0.83 0.28–2.42 115 (39.0) 0.62 0.44–0.87 1.23 0.42–3.61
Postmenopausal HRT duration
Never 219 (50.3) 13 (59.1) 1.00 --- 180 (61.0) 1.00 --- 1.00 ---
<5 years 105 (24.1) 3 (13.6) 0.60 0.14–2.51 56 (19.0) 0.61 0.40–0.92 1.37 0.30–6.24
5+ years 111 (25.6) 6 (27.3) 1.07 0.31–3.70 59 (20.0) 0.64 0.42–0.96 1.17 0.35–3.91
aORs adjusted for sampling fraction, age, race, menopausal status (where appropriate), first-degree family history of breast cancer, parity/age first 
full-term pregnancy, breast feeding (ever, never), smoking status (never, former, current), alcohol intake (ever, never), age at menarche (<11, 11–
12, 13, 14+), and body mass index (<25, 25 to <30, 30+). CI, confidence interval; ESR1, estrogen receptor alpha; HRT, hormone replacement 
therapy; OC, oral contraceptive; OR, odds ratio.Page 6 of 10
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tests were not statistically significant.
Among postmenopausal women, there was no clear evidence
for an association of HRT use with ESR1 A908G mutation-
positive cancer (OR = 0.83, 95% CI = 0.28 to 2.42), but HRT
use was inversely associated with mutation-negative breast
cancer (OR = 0.62, 95% CI = 0.44 to 0.87 for ever users; OR
= 0.64, 95% CI = 0.42 to 0.96 for duration of 5 or more years)
(Table 2). We were unable to analyze HRT according to former
and current use because the numbers in each case group
were too sparse.
First-degree family history of breast cancer was associated
with ESR1 mutation-positive breast cancer (OR = 2.54, 95%
CI = 1.16 to 5.55) (Table 1). Further adjustment for OC use
had little effect on this association (OR = 2.71, 95% CI = 1.16
to 6.33). These results suggest that OC use and family history
of breast cancer may independently influence risk of the ESR1
mutation-positive subset of breast cancer.
Discussion
Evidence is accumulating to suggest that breast cancer is a
collection of biologically distinct disease subtypes character-
ized by unique gene expression profiles, molecular or protein
markers, and that exhibit variable clinical behavior, prognosis,
and response to therapies [9,10,18-21]. Similarly, data
obtained from some epidemiologic studies of breast cancer
suggest that tumor subsets classified according to certain
somatic or protein expression changes may be associated
with specific etiologic risk factors [17,22-26]. Consistent with
this, our study has revealed that first-degree family history of
breast cancer (or breast and/or ovarian cancer) may be a risk
factor for breast tumors carrying the ESR1 A908G mutation.
Recent (within 10 years) and long-term (more than 10 years)
use of OCs may also be associated with mutation-positive
breast cancer; however, due to small numbers, most of these
results were not statistically significant. In contrast, mutation-
negative breast cancer was not associated with OC use but
instead was associated with several reproductive factors,
including longer duration of ovarian function and younger age
at menarche, which increase exposure to endogenous hor-
mones. HRT use was inversely correlated with the mutation-
negative breast cancer subtype, but due to the small number
of postmenopausal cases carrying the mutation, an effect of
HRT on ESR1 A908G mutation-positive breast cancer could
not be adequately assessed.
Many hormonal or reproductive factors that increase exposure
to estrogen and/or progesterone are risk factors for breast
cancer [1], and the contribution of OC use to breast cancer
development has been extensively researched. Recent and
longer durations of OC use have shown the most consistently
positive, though small, associations with breast cancer [27-
35], observations which are compatible with our findings for
the ESR1 A908G mutation-positive cases. The 1996 meta-
analysis of the published data on breast cancer risk and hor-
monal contraceptives by the Collaborative Committee on Hor-
monal Factors in Breast Cancer, the most comprehensive
assessment of the impact of OCs on breast cancer risk [30],
found that current and recent users of combined OCs had a
small increased risk of breast cancer which decreased with
time such that no significant excess risk remained 10 years
after last use. Breast tumors that developed among ever OC
users were less likely to have distant metastases; however,
other characteristics of the primary tumor were not specifically
evaluated. Young age at first use of OCs and use before the
first full-term pregnancy carry elevated risks for breast cancer
in several studies [28,32,35]; however, we found only a small,
non-significant association with later age at first use of OCs
among the ESR1 A908G mutation-positive subgroup. Addi-
tionally, associations with OCs have been noted among some
subsets of breast cancer cases, including younger women
[27,28,35], those with a family history of breast cancer [36],
germline mutations in BRCA1 or BRCA2 [37-39], or other
genetic polymorphisms [40]. Case subgroups defined by cer-
tain tumor characteristics have been associated with OC use,
including lobular or mixed lobular/ductal histology [41], and
those expressing ER [26], HER2 [17], p53 [23], or cyclin D1
[24].
In our study, ESR1 A908G mutation-positive breast cancer
was strongly associated with recent and long-term OC use
even though there was only a small main effect of OC use in
the CBCS [31]. This finding suggests that characterization of
breast tumors according to ESR1 A908G mutation status may
help to uncover a subgroup of women for whom OC use may
be a stronger risk factor. Furthermore, the mutation-negative
subgroup may be associated with certain risk factors that rep-
resent greater exposure to endogenous hormones. Li and col-
leagues [42] noted distinct effects of exogenous versus
endogenous hormonal factors on tumor histology, with OC
use being more strongly associated with the development of
lobular and mixed lobular/ductal breast tumors whereas
endogenous hormonal factors, including longer duration of
ovarian function and higher BMI, were more strongly associ-
ated with risk of ductal breast cancer. Several other case-con-
trol studies have also found that use of combined HRT or OC
was associated mainly with an increase in lobular and mixed
lobular/ductal breast cancer [41,43,44]. The relationship
between ESR1 A908G mutation-positive breast cancer and
OC use is not surprising as the mutation-positive subgroup of
tumors in the CBCS was more likely to have mixed lobular/
ductal histology [14].
These results suggest the possibility that endogenous and
exogenous hormones may be differentially associated with
development of breast cancer characterized by the presence
or absence of the ESR1 A908G mutation. The exact basis for
this is unclear but could be related to qualitative and/or quan-Page 7 of 10
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estradiol (and/or progesterone), the timing of exposure to
OCs, or differences in the biological effects elicited by the
mutant and wild-type receptors.
Exposure to OCs, particularly the estrogen component,
increases proliferative activity in breast epithelium [45-50].
The ESR1 A908G mutant was reported to be hypersensitive
to estrogen and was associated with cellular proliferation at
sub-physiologic levels of estradiol in vitro compared with the
wild-type receptor [11]. Additionally, the A908G mutation was
originally detected in breast hyperplasias [11], which may be
risk factors and, in some instances, early precursors of invasive
breast cancer [51-53]. We have also detected this mutation in
benign breast lesions that contain histologic features other
than usual hyperplasia (K. Conway, unpublished data). Given
the abnormal function described for this somatic ESR1
A908G variant and its presence in very early breast lesions, it
is biologically plausible that exposure of breast tissue to exog-
enous hormones during the premenopausal years could be
associated with the subgroup of breast tumors carrying this
mutation. From a mechanistic standpoint, our results suggest
that OCs could interact with the pre-existing ESR1 A908G
mutant receptor in early pre-neoplastic breast lesions to stim-
ulate epithelial proliferation, thus driving the accumulation of
additional genetic errors leading to neoplasia. The possibility
that such a common exposure as OC use might stimulate the
outgrowth of cells carrying this somatic mutation makes the
ESR1 A908G variant a potentially important candidate marker
for studies of breast cancer etiology and progression.
Studies on combined estrogen and progestin HRT have gen-
erally found longer duration and recent use of HRT to be asso-
ciated with increased risk of breast cancer [54]. HRT with
estrogen alone or combined estrogen and progestin is associ-
ated with increased proliferation in normal breast tissue of
postmenopausal women [55]. Postmenopausal HRT use was
somewhat protective for the mutation-negative subgroup, sim-
ilar to what was previously reported overall in the CBCS [56].
Compared with controls, breast cancer cases in the CBCS
with ESR1 A908G mutation-positive tumors were more likely
to have a first-degree family history of breast cancer whereas
the mutation-negative cases were not; this finding was sup-
ported by case-case comparisons. This association is unlikely
to be related to germline defects in BRCA1 or BRCA2 since
21 of the 37 ESR1 mutation-positive cases had previously
been screened for mutations in these genes but none was
found [57] (B Newman and M-C King, unpublished data).
However, we cannot rule out the possibility that these cases
may carry germline variations in other genes which could influ-
ence breast cancer susceptibility and which include variants
within ESR1 that may be linked with mutation status. Several
previous studies have evaluated the risk of breast cancer asso-
ciated with OC use among women with a family history of
breast cancer [33,40,58] or those carrying germline defects in
BRCA1 or BRCA2 [37-39]. Grabrick and colleagues [36]
suggested that OC use was more strongly associated with
breast cancer among women with a family history, but at least
two subsequent studies have not supported this finding
[29,58]. However, in some studies, OC use has been found to
increase breast cancer risk among women with known
BRCA1 or BRCA2 germline variants [37-39].
The primary strengths of this study are the population-based
case series comprised mainly of early stage tumors, the careful
assessment of the ESR1 A908G mutation by means of a strin-
gent screening algorithm, and the large sample size nearly half
of which consisted of premenopausal women. Despite the
large number of cases evaluated (n = 653), this study is limited
by the small number of mutation-positive breast tumors identi-
fied. Therefore, our results should be interpreted with caution.
However, the significant findings on OC use and ESR1
A908G mutation-positive breast cancer warrant further study
in larger data sets.
Conclusion
Characterization of breast tumors for the ESR1 A908G point
mutation, shown by Fuqua and colleagues [9] to be hypersen-
sitive to estrogen, may reveal important etiologic clues. ESR1
A908G mutation-positive breast cancer was significantly
associated with longer duration and recent use of OCs and
with a first-degree family history of breast cancer, suggesting
that OCs may interact with the ESR1 A908G mutant receptor
in the development of some breast tumors. Some reproductive
factors linked to greater exposure to endogenous hormones,
including younger age at menarche and longer duration of
ovarian function, were associated with the mutation-negative
subgroup, suggesting that endogenous hormonal factors may
be more important for mutation-negative cancer. Additional
studies will be required to confirm these findings.
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